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Anabolic Steroids in the UK: An increasing issue for Public Health 
Abstract  
Aims: The aim of the paper was to identify changes in the extent and patterns of 
anabolic steroid use in the United Kingdom to better understand the public health 
implications within the context of the current health-related evidence base. 
Methods: Using the two time points of 1995 (prior to legislation changes in the United 
Kingdom) and 2015, a review of the evidence related to health harms was conducted, 
in conjunction with needl  and syringe programme (NSP) data in Cheshire & 
Merseyside (UK) relating to anabolic steroid users. 
Findings: Dramatic increases in the numbers of anabolic steroid users accessing NSPs, 
553 in 1995 to 2446 in 2015, now accounting for 54.9% of clients. With the inclusion of 
pharmacy NSPs, this rose to 5336 individual anabolic steroid users. 
Conclusions:  Key changes in our knowledge during the 20 years, in particular in 
relation to HIV prevalence, changes in the market and patterns of use make anabolic 
steroid use a public health concern. In the context of increasing numbers of injectors, 
there is a need for comprehensive interventions.   
Key words: Anabolic Steroids, Needle and Syringe Programmes, HIV. 
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Anabolic Steroids in the UK: An increasing issue for Public Health 
Introduction 
Whilst the media and much of society have focused on the use of drugs to enhance 
performance in elite sport, ‘doping’ or ‘cheating’, the reality is that the 21st century has seen 
the use of anabolic steroids become commonplace within the general population of a number 
of countries, including the United Kingdom. The modern era of anabolic steroids commenced 
in the early part of the 20th Century. This was largely due to pharmacological developments, 
with the isolation of testosterone (de Kruif, 1945) and the rapid expansion of patent and secret 
remedies (British Medical Association, 1909). During the last twenty years, with advances in 
pharmacology, technology and the introduction and expansion of the Internet, there has been 
an unprecedented increase in interest, availability and use of enhancement drugs in general, 
and anabolic steroids in particular (Evans-Brown et al., 2012). The term anabolic steroids 
(sometimes termed anabolic androgenic steroids) relate to testosterone and its synthetic 
derivatives. Anabolic steroids are used illicitly for enhancing muscle growth and strength, 
boosting physical activity or sports performance, and for aesthetic purposes (Sagoe et al., 
2014). There are few circumstances in which anabolic steroids are prescribed. Similarly, 
human growth hormone has limited medical uses (Evans-Brown & McVeigh, 2009). 
It is these muscular enhancement drugs, anabolic steroids and associated substances 
that this paper will examine, and take stock of the relative risks to the population. As our 
understanding of the actions of these drugs and the potential consequences of their self-
directed use has become more apparent over the last 20 years, we ask the question:  
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‘What are the public health implications of anabolic steroids and associated drugs 
in 2016?’  
To assess the situation in the United Kingdom as it currently stands, comparisons between the 
situation in 1995 and 2016 will be made. With the major changes in anabolic steroid 
legislation occurring in 1996 (ACMD, 2010), it is an appropriate timeframe to examine. The 
paper will review the available evidence with relevance to the United Kingdom at these two 
points in time in relation to drug related harms and the practices employed by anabolic steroid 
users. This will be supplemented by data from needle and syringe programmes in the North 
West of England, for the year 1995 and 2015. 
Background 
The mid 1990’s 
Anabolic steroids have long been associated with a range of adverse effects, from the 
cosmetic and transient to the life-threatening (ACMD, 2010). However, much of the data 
relating to health harms are derived from case reports/series and cross-sectional studies that 
are observational in nature (Evans-Brown et al., 2009). This led Friedle (2000) to conclude 
that, based on the information available, (with the exception of orally active anabolic steroids) 
there was only limited evidence related to many of the potential adverse consequences of 
anabolic steroid use. This followed a detailed review of case reports of serious illness and 
death amongst athletes with associated anabolic steroid use. Between 1977 and 1995 
relatively few cases were described, including several forms of cancer, myocardial infarctions 
and rare cases of HIV. Cerebrovascular thrombosis was singled out as a danger, with the 
1980s and early 1990s also witnessing the emergence of cardiomyopathy secondary to 
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anabolic steroids as a cause for concern (Ferenchick, 1996; McKillop et al., 1986). The safe 
use of testosterone as a male contraceptive provided a backdrop to this relative lack of 
concern (WHO, 1990).  
At this time, the main threat appeared to be from the 17-alkylated anabolic steroids 
(these include oral anabolic steroids such as, methandienone and oxymetholone which are still 
in common usage today, Hope et al., 2013) with cases of acute liver toxicity resulting in 
serious damage. Cross-sectional data indicated impaired liver function in some users but it 
was not long before even this was questioned due to the difficulties in distinguishing between 
markers of hepatotoxicity and markers of muscle damage secondary to high-levels of 
resistance exercise (Dickerman et al., 1999). 
Psychological harm and behaviour changes were cited as concerns at this time. 
Increasing evidence from the USA, in particular the work of Pope and colleagues (Pope, 
1994; Pope & Katz, 1992) illustrated the potential for psychological harms. Wide ranging 
effects (Parrott et al., 1994; Perry & Hughes, 1992) including aggression (Su et al., 1993) and 
violence (Choi & Pope, 1994; Malone et al. 1995; Pope & Katz, 1990; Schulte et al., 1993) 
associated with the use of anabolic steroids were described in the literature. Interviews with 
anabolic steroid users in the United Kingdom in the mid-1990s revealed that 54% had 
experienced feelings of aggression (Lenehan et al., 1996) supporting the earlier work by 
Korkia & Stimson (1993), with findings not restricted to male users (Korkia et al., 1996). 
Our understanding of the knowledge and practices of anabolic steroid users in the 
United Kingdom at that time largely stemmed from the work of Korkia and Stimson (1993), 
in which 110 steroid users were interviewed and the 386 interviews conducted in the North 
West of England by Lenehan et al,. (1996). While polypharmacy was common, it was usually 
restricted to a small number of anabolic steroids combined with drugs such as tamoxifen 
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citrate and human chorionic gonadotrophin to combat unwanted side effects. The use of 
human growth hormone was rare amongst users of anabolic steroids, at 2.7% in the United 
Kingdom study (Korkia and Stimson, 1993) and 5.7% in the North West of England study 
(Lenehan et al,. 1996). 
The main source of information for users of anabolic steroids was the gym owner, 
followed by handbooks, (usually from the United States) with the Anabolic Reference Guide 
(Phillips, 1991) and the Underground Steroid Handbook II (Duchaine, 1989) being 
particularly popular. The central role of the gym owner was explored further with interviews 
conducted with 64 gym owners across the North West of England. Their main areas of 
concern related to the lack of reliable information on anabolic steroids and the amount of fake 
and counterfeit products on the market (McVeigh, 1996). The former is of interest as the 
subsequent expansion of the Internet would change beyond recognition, the amount of 
information available to anabolic steroid users, although not the central tenet of ‘reliable 
information’.  The latter is interesting as this was an area of concern that was only just 
emerging within the academic literature (McVeigh & Lenehan, 1994; Musshoff et al., 1997; 
Perry, 1995; Walters et al., 1990). A third issue of concern raised by gym owners related to 
the use of anabolic steroids by young people. Over three-quarters of gym owners had 
observed increasing numbers of young males attending their gyms, ‘…using anabolic steroids 
without any understanding of potential harms’ (McVeigh & Lenehan, 1994).  
It was this final issue, supported by data from studies in the United Kingdom 
(Williamson, 1993), Canada (Melia et al., 1996) and numerous studies from the United States 
(including Buckley, 1988; DuRant et al., 1995; Johnson et al., 1989) that influenced 
legislative changes, bringing anabolic steroids and associated drugs under the control of the 
Misuse of Drugs Act (1971) in the United Kingdom. 
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On 1st September 1996, anabolic steroids and a number of associated drugs including 
growth hormones became controlled under the Misuse of Drugs Act (1971), following a 
recommendation from the Advisory Council for the Misuse of Drugs. Prior to the change in 
legislation, anabolic steroids came under the jurisdiction of the Medicines Control Agency, an 
arm of the Department of Health (ACMD, 2010). In April 2012, the phrase “medicinal 
product” was removed to reduce ambiguity and import restrictions placed on buying anabolic 
steroids and associated drugs from outside the United Kingdom. Anyone wishing to import 
these drugs from outside the United Kingdom is now required to do so in person (sometimes 
referred to as ‘personal custody’). These changes were put in place in an attempt to curb the 
large anabolic steroid online market. Personal possession of these substances remains legal in 
the United Kingdom. However, Supply offences, including possession with intent to supply, 
carry a maximum sentence of 14 years and/or an unlimited fine (PHW, 2016).   
2016 
While there remains significant gaps in our knowledge and understanding of anabolic steroids 
and associated drugs, many of the conditions that were considered to have the potential to 
cause adverse effects now have a much firmer evidence base.  Much of this work has been 
conducted in North America, with contributions from Europe (in particular the Nordic 
countries) and Australia and are summarised in the Endocrine Society Scientific Statement 
(Pope et al., 2014). The statement highlights a number of adverse effects of anabolic steroids 
on various organs and systems of the body including hematologic effects, hepatic, 
musculoskeletal, renal, immunological and dermatological, together with hormonal and 
metabolic effects.  Perhaps the greatest concern is reserved for the cardiovascular impact. 
Building on the extensive catalogue of cardiac damage (Angell et al., 2012), controlled 
studies have provided a greater understanding of potential harm to the heart such as 
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hypertrophy and electrical instability  (Baggish et al., 2010; Far et al., 2012; Krieg et al., 
2007). Another area of increased understanding, relates to psychiatric, neuropsychologic and 
behavioural impact of anabolic steroids. The hypotheses of the mid 1990s have subsequently 
been supported in work within the general population and prison population (Klötz et al., 
2010; Lundholm et al., 2010; Pope et al., 2000). There remains many unanswered questions 
relating to aggression and violence (Mazur, 2005) and the wider psychological effects of 
anabolic steroids including anxiety, depression and dependence. However, there is some 
consensus, that for many, anabolic steroids will have a relatively minor impact on behaviour 
and mental health, but for some the consequences can be severe (Pope et al., 2014). Even 
within the user population there are contradiction and ambivalence (Kimergard, 2015; 
Monaghan, 2001). It also appears that the anabolic steroid regimes employed (combinations 
and dosages), length of use, underlying psychological wellbeing and mental health, 
concomitant use of recreational psychoactive drugs may all pay a part in the extent of the 
adverse consequences of use. 
There are several additional concerns, the extent of which had not been fully 
recognised 20 years ago. They are not pharmacological adverse effects and may even be 
considered as ‘indirect effects’, but from a public health perspective, have major implications. 
They relate to the drugs market and the method of administration respectively. The majority 
of available anabolic steroids are illicitly manufactured (ACMD, 2010; Evans-Brown et al., 
2009; Evans-Brown et al., 2012; Graham et al., 2009; Kimergard et al., 2014a). This is not 
unique to the United Kingdom market (Cohen et al., 2007; Larance, 2005; Parkinson & 
Evans, 2006; Striegel et al., 2006). Without the requisite quality assurance of legitimate 
manufacture, products are often contaminated with biological, chemical or foreign matter, 
variable in strength or substituted with different active ingredients. This has clear implications 
for health in relation to infection, over-dosage and unexpected adverse consequences (Thevis 
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et al., 2008). This is not just an issue related to anabolic steroids but effects all illicitly 
manufactured image and performance enhancing drugs e.g. peptide hormones (Kimergard et 
al., 2014b), growth hormone releasing hormones (Stensballe et al., 2015), melanotan II 
(Breindahl et al., 2015), 2,4-Dinitrophenol (McVeigh et al., 2016) and even dietary 
supplements adulterated with anabolic steroids (Abbate et al., 2015) or ancillary drugs such as 
tamoxifen (Evans-Brown et al., 2014). 
A further concern is how the substances are used. While polypharmacy has been the 
norm for in excess of 20 years in the United Kingdom (Korkia, 1993; Lenehan et al., 1996; 
McBride et al., 1996), there is unprecedented availability of a vast array of substances, some 
long established while others are still at the experimental stage (Chandler & McVeigh, 2014; 
Hope et al., 2013; McVeigh et al., 2015). This is not unique to the United Kingdom but a 
global issue (Larance et al., 2008; Parkinson & Evans, 2006; Sagoe et al., 2015; Skarberg et 
al., 2009).  The most dramatic change in the use of drugs in conjunction with anabolic 
steroids, is the issue of human growth hormone. Similarly to the findings of Parkinson and 
Evans (2006), the United Kingdom, has experienced falling costs of producing and 
purchasing human growth hormone. In the 1990s growth hormone was purchased at between 
£6.58–£20 per IU (International Unit). By 2008, the price had fallen to £1.00– £8.33 per IU 
(Evans-Brown & McVeigh, 2009).  This has resulted in 32% of current anabolic steroid users 
having used human growth hormone in the previous year (Hope et al., 2013). 
In addition to these changes in relation to anabolic steroids in the United Kingdom, a 
significant public health issue has emerged. Until recently, HIV and other blood borne virus 
prevalence and transmission was largely dismissed as a marginal public health concern. Case 
reports of HIV amongst users of anabolic steroids have been rare (Henrion et al., 1992; Scott 
& Scott, 1989; Sklarek et al., 1984), surveillance of injecting drug users has failed to detect 
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HIV amongst this population (Crampin et al., 1998) and the identification of the sharing of 
injecting equipment less common than amongst those who inject psychoactive drugs both in 
the United Kingdom (Midgley et al., 2000) and Australia (Iversen et al., 2013; Larance et al., 
2008). 
In 2013, the largest study of blood borne viruses in users of anabolic steroids and 
associated drugs was published. Samples from 395 men revealed that 1.5% had HIV, 9% had 
antibodies to the hepatitis B core antigen (anti-HBc) and 5% to hepatitis C (anti-HCV) (Hope 
et al., 2013). Furthermore, 36% reported having redness, swelling and tenderness in the 
preceding year, and 6.8% had experienced an abscess or open wound at an injection site at 
some point in the past (Hope et al., 2015).  Data from a subsequent survey (2012-2013), 
together with historical data were analysed, demonstrating that the blood borne virus 
prevalence among this population of  injectors has increased, and levels of HIV are now 
similar to that amongst psychoactive drug injectors (Hope et al., 2016).  
It is within this context of increasing public health concern regarding the use of 
anabolic steroids and associated drugs that the needle and syringe programme (NSP) 
monitoring system data at Liverpool John Moores University was interrogated to identify the 
extent of anabolic steroid use within the North West of England. 
Methods 
The NSP monitoring data from the years 1995 and 2015 were extracted to provide an 
indication of the number of anabolic steroid injectors accessing these services. There has been 
significant changes to the NSP surveillance system during the period between 1995 and 2015, 
however the monitoring principles remain the same. The earlier datasets were collected in 
paper format and manually entered onto a database, technological advances allowed for the 
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latter datasets to be reported directly onto the Integrated Monitoring System (IMS) via online 
submissions or shared from services’ own data collection systems. The system enables each 
transaction to be attributed to a specific individual. The client provides an attributor code 
(entailing initials, date of birth and sex), together with data relating to the drugs of injection 
enabling all subsequent visits and details of transaction to be recorded and attributed. The use 
of an attributor code such as this is now widely used within monitoring and surveillance 
systems in relation to substance use (for details on the Integrated Monitoring System see 
Whitfield et al., 2015). Data for all agency NSPs across Cheshire and Merseyside were 
analysed using SPSS v22 for the years 1995 and 2015 respectively. Figures were aggregated 
to Local Authority level (Cheshire, Halton, Knowsley, Liverpool, Sefton, St Helens, 
Warrington and the Wirral) and then further aggregated to provide totals for Cheshire and 
Merseyside as a whole. Client records were omitted if client’s date of birth was less than 10 
years of age.  
Population data were derived from mid-1996 and mid-2014 with the age category 20-
29 used to calculate prevalence of steroid using NSP clients per 1,000 population. For 2015, 
an additional measure of ‘all sources’ was calculated. Not available in 1995, these figures 
relate to the total number of individual anabolic steroid users attending either agency NSP or 
pharmacy NSP. Further aggregation is included to remove duplicates across the two data 
sources. Table 2 relates to individual steroid using clients including the total number of 
syringes provided to each individual user.  
Results 
[Table 1 near here] 
Cheshire and Merseyside, with a total population of 2,430,284 (ONS, 2016) was served by 18 
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agency NSPs in 2015, and 17 agency NSPs in 1995. A total of 2,446 individual steroid users 
accessed agency needle and syringe programmes across Cheshire and Merseyside in 2015 
compared with 553 in 1995, representing a 342% increase over the period. Changes were not 
uniform across the geography, with dramatic increases in the Local Authorities in the County 
of Cheshire, Halton (HAL) (2,633%), Cheshire (1,321%) and Warrington (WAR) (703%). In 
the more urbanised County of Merseyside, increase was pronounced but more modest, with 
the central Local Authority of Liverpool (LIV), reporting a decrease of 31%. 
Data indicate that anabolic steroid use is most common in the male age group of 20 to 
29. This has been calculated for both years, indicating an increase from 1.88 per 1,000 
population to 5.72 per 1,000 population. There exists a wide variation in the number of steroid 
users accessing NSPs per 1,000 population in the Local Authorities, rising as high as 16.78 in 
St Helens (SHL) and 18.76 in Halton (HAL). 
All steroid users (all sources) incorporates data from the agency NSP and Pharmacy 
NSP and is only available for 2014/15. The pharmacy data were obtained from 84 shops 
across Cheshire and Merseyside. Direct comparison of the total of number of anabolic steroid 
users in 2015 (5,336) cannot be made with the agency only data of 1995 (553). However, 
contemporary data from the mid-1990s indicates that the vast majority of injecting equipment 
provided from these outlets were suitable for intravenous injection only and would not be 
suitable for intramuscular anabolic steroid injection (Birtles & Bellis, 1997), therefore 
enabling some level of comparison. This would indicate an even more dramatic increase in 
NSP provision for anabolic steroid users. While most Local Authorities experienced an 
increase in anabolic steroid user totals with the inclusion of the additional data source, the 
most dramatic increase occurred in Cheshire. 
[Table 2 near here]  
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The majority of agency NSP clients in Cheshire and Merseyside are injectors of 
anabolic steroids and associated drugs. During the last 20 years, the percentage of steroid 
users has risen from 17.1% to 54.9% and with males now accounting for 98.6% of all steroid 
using clients compared to 96.5% in 1995. The mean age of steroid using clients also increased 
from 26 years old (median age of 25) in 1995 compared to 31 years old (median age of 30) in 
2015. The total number of syringes dispensed rose from 14,293 to 139,956, an increase of 
879%. This is not just as a result of an increased number of steroid users accessing NSPs but 
equates to more than a doubling of equipment per client. 
Discussion 
The last 20 years has witnessed significant changes in relation to substance use in general, not 
least in relation to the use of human enhancement drugs (Evans-Brown et al., 2012). Nowhere 
is this more pronounced than in the use of anabolic steroids and associated drugs, the number 
and diversity of drugs being used (Sagoe et al., 2015), the accompanying psychoactive drug 
use (Hope et al., 2013) and the massive dosages being used by even the most novice of users 
(Chandler & McVeigh, 2014).  
Increased research and opportunities to publish have seen an unprecedented amount of 
peer reviewed papers published on anabolic steroid use. In a basic search of academic papers 
using CINAHL, PsychINFO, Social Sciences Citations Index and Medline for relevant papers 
on the use of anabolic steroids and associated drugs, 95 unique references were generated for 
1995 compared with 397 for 2015. While this is partly as a result of the expansion of the 
Internet, still the majority of steroid users access their information from non-academic sources 
on the Web (Kimergard & McVeigh, 2014c). The academic literature has provided a greatly 
improved understanding of the potential adverse effects of anabolic steroids and a range of 
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associated drugs (Pope et al, 2014) and this will continue to improve as anabolic steroid users 
mature and the longer term impact of high levels of sustained drug use can be ascertained. 
The above issues are compounded by the fact that the vast majority of available products are 
manufactured illicitly or without due oversight in relation to ‘quality, safety and efficacy’ 
(MHRA, 2007) undermining the further development of the evidence base and basic harm 
reduction messages related to the specific substances and dosages (Evans-Brown et al., 2009). 
The identification of HIV within this population is a significant concern. While we are 
unable to identify if the transmission is due to the sharing of anabolic steroid injecting 
equipment, sharing of equipment linked with previous (or current) psychoactive drug 
injection, sexual transmission or a combination of all these routes, the fact that it is 
established within the population, at the same level of that seen in psychoactive drug injectors 
has profound public health implications (Hope et al., 2013; Hope et al., 2015).  
Clearly, to ascertain the extent of a potential public health issue, an estimate of the 
prevalence or at least an indication of the scale of the particular activity is required. We have 
some indication of prevalence of anabolic steroid use, Sagoe et al, estimated that the global 
lifetime prevalence for anabolic steroids is 3.3% with higher levels across Europe (Sagoe et 
al, 2014). The Crime Survey for England and Wales (2014/15) suggests much lower levels of 
0.9%, although a statistically significant rise over the previous decade, with approximately 
73,000 having used in the previous year (ONS, 2015). The Crime Survey for England and 
Wales is generally accepted to be a considerable underestimation of anabolic steroid use 
(ACMD, 2010; Bates et al., 2014). Previously published work has provided an indication as to 
the extent of anabolic steroid users at NSPs, in the geography examined here (McVeigh et al, 
2003a; ACMD, 2010) and across the wider United Kingdom (Kimergard & McVeigh, 2014c). 
This is however, the first time that a comparison over a prolonged period has taken place. The 
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data illustrate a startling increase in the number of anabolic steroid users accessing NSPs. This 
cannot be used as a true proxy for changes in the prevalence of anabolic steroid use, as it may 
reflect an increased proportion of anabolic steroid users presenting to these services. This may 
be at least partially countered by the increased number of syringes being dispensed. It is long 
established that many steroid users in the United Kingdom will be provided with injecting 
equipment for other users of anabolic steroids (Korkia & Stimson, 1993, Lenehan et al., 1996; 
Cullen et al, 2015) with this practice recognised by National Institute for Health & Care 
Excellence (NICE, 2014) and mirrored in Australia (Dunn et al., 2014). While there have been 
changes over time in relation to the number and frequency of injections, we suggest that the 
139,956 syringes provided by agency NSPs alone (this does not include the equipment 
dispensed from pharmacy NSPs or purchased online) is an indication of a large and growing 
population of anabolic steroid users. 
It is of interest to consider the different patterns of change across the Local 
Authorities. Increases are by no means uniform, with stark contrast between the urban area of 
Liverpool to the more rural and affluent Cheshire. Th  inclusion of pharmacy data confirms 
that the different situation in Liverpool is not masked by a migration from one type of NSP to 
another. We hypothesise that this may at least partly be explained by a diffusion of high levels 
of anabolic steroid use from the central Liverpool area in the mid-1990s to the outer areas of 
Cheshire and Merseyside over the last 20 years. 
While the origins of the diffusion theory can be traced back to the early 1900s (De 
Tarde, 1903), it is Rogers’ Diffusion of Innovation (1983) and its application to drug use 
behaviour (Rogers, 1995) that support this explanation. Golub et al. (2005) describe a 
complex interaction of culture and individualism with drug use being an active decision 
where the ‘setting’ (Zinberg, 1984) is the main influence. The ‘trickle down’ effect of 
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innovators and early adopters may explain the later adoption of high levels of anabolic steroid 
use occurring in the central urban section of the geographical area, spreading to the 
suburban/rural areas over time. This has similarities to previous phenomena that took place in 
Cheshire and Merseyside during the 1980s in relation to heroin use and the 1990s, in which 
the adoption of crack cocaine could be traced as emanating in Central Liverpool before 
expanding its reach across the region (McVeigh et al., 2003b). 
There is a lack of evidence based interventions in relation to anabolic steroids. 
Currently, there are no formal academic evaluations of harm reduction, treatment or 
prevention interventions in the United Kingdom.  Furthermore, there is scant evidence 
internationally (Backhouse et al., 2014). While prevention programmes such as ‘Hercules’ 
appear promising (implementation of a theoretical learning base and practical strength 
training sessions, Sagoe et al, 2016) in relation to positive changes in knowledge, similarly to 
other programmes, we do not have evidence of longer term positive behaviour change (Elliot 
et al., 2008; Fritz et al., 2005; Goldberg et al., 2007; Jalilian et al., 2011; Nilsson et al., 2004). 
With evidence of a range of serious health harms, not least the identification of HIV within 
the population, and indications of increasing prevalence, public health cannot wait for 
effective prevention interventions to be established and the need for a comprehensive harm 
reduction approach is required. Whilst the data here show an increasing number of anabolic 
steroid injectors attending needle and syringe programmes, it is recognised that this represents 
only a subset of this population and greater engagement efforts need to be made through 
outreach to gyms and other environments where anabolic steroid use is likely to be found 
(such as the night-time environment and occupations where size, strength or appearance are 
highly valued).  
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 Conclusion 
Clearly, there have been significant changes in our understanding of anabolic steroid use 
together with the extent and practices of the users themselves. The recent identification of 
HIV within the population, the quality and safety of the illicit products being used, together 
with the established physical and psychological harms are causes for concern. The NSP 
surveillance system in Cheshire & Merseyside provides evidence for the extent of anabolic 
steroid use, a phenomenon that is believed to be replicated across the United Kingdom and 
beyond. Detailed work is required relating to the causes and drivers of this situation, the risk 
behaviours of the individuals, the nature of the illicit market and role of the Internet together 
with the development of (cost) effective demand and harm reduction. 
Limitations 
The paper is set within a United Kingdom context and while some themes will be 
transferrable to other countries, the specifics related to legislation, service provision and to 
some extent cultural background, limits the extent to which it is generalizable. Furthermore 
the extent to which Cheshire and Merseyside is representative of the United Kingdom as a 
whole remains unknown, therefore there is a clear need for further research and surveillance 
within this particular population across wider geographies and over time.  The literature 
reviews relating to the mid-1990s and 2015 are not systematic with potential bias towards 
work by the authors due to the nature and geography of their work. The data relating to the 
attendance at needle and syringe programmes is self-reported surveillance in nature with some 
differences in data collection methods (paper compared to electronic). We have no reason to 
believe that this would in any way skew the findings. 
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Table 1: Anabolic steroid users accessing needle and syringe programmes in Cheshire and Merseyside, United Kingdom during 1995 and 2015 
 
LA/DAT 
 
1995 No. of 
steroid 
users 
 
2015 No. of steroid 
users 
1995 Male steroid users 
aged 20-29 
2015 Male steroid users  
aged 20-29 
2015 
No. 
users 
Total 
Pop 
Users per 1000 
population 
No. 
users 
Total 
Pop 
Users per 1000 
population 
All steroid 
users 
(all sources) 
Cheshire 29 412 17 42468 0.40 238 38083 6.25 1214 
HAL 12 328 10 8350 0.24 145 7731 18.76 616 
KNW 25 178 15 10119 1.48 79 9444 8.37 178 
LIV 223 153 164 36298 4.52 55 47145 1.17 278 
SEF 40 85 25 16935 1.48 33 15647 2.11 791 
SHL 45 411 33 12187 2.71 180 10729 16.78 605 
WAR 29 233 17 12908 1.32 122 12525 9.74 677 
WIR 150 646 96 18736 5.12 276 17697 15.60 980 
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Total 553 2446 377 200469 1.88 1128 197084 5.72 5336 
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Table 2: Service uptake by anabolic steroid users accessing needle and syringe programmes 
in Cheshire and Merseyside, United Kingdom during 1995 and 2015 
  
Variable 1995 2015 
Proportion of total NSP clients 17.1% 54.9% 
Proportion male 96.5% 98.6% 
Sum of syringes 14293 139956 
No of syringes per individual 26 57 
Age of male NSP clients   
Mean 26 31 
Median 25 30 
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